Try our Advanced Search for more refined results
Track this case
IPR2022-00608
IPR
Final Written Decision - Appealed
Penumbra, Inc.
Filed: February 15, 2022 00:00
The Patent Trial and Appeal Board has found medical device company Penumbra Inc. was able to show that numerous claims in a patent on a treatment for strokes caused by blood clots were invalid, saying the claims were obvious.
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login
Email (NOTE: Free email domains not supported)
First Name
Last Name
Job Title
PLEASE NOTE: A verification email will be sent to your address before you can access your trial.
Password (at least 8 characters required)
Confirm Password
Law360 may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.We take your privacy seriously. Please see our Privacy Policy.